The present invention addresses the problem of providing a means for removing mutant mtDNA from a cell after homoplasmization of the cell. The present invention relates to: a homoplasmization promoter that comprises a reactive oxygen species or a chemical species which generates a reactive oxygen species in a cell, and a mitophagy promoter, or that comprises a substance that has the effect of generating a reactive oxygen species in a cell and the effect of promoting mitophagy; and a homoplasmization promotion method which uses the homoplasmization promoter. The present invention also relates to: a method for using the homoplasmization promotion method to prepare a homoplasmic cell; and a homoplasmic cell produced by said method.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61Q 19/00 - Préparations pour les soins de la peau
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
Provided is a method for producing naive induced pluripotent stem cells from human somatic cells, comprising the following steps (1) to (3): (1) introducing one or more vectors containing a reprogramming factor into human somatic cells, (2) culturing said somatic cells in the presence of a naive medium, and (3) after step (2), culturing the resulting cells in the presence of the naive medium under the condition in which the amount of the vectors per the somatic cell is reduced to 30% or less of that at the start of step 3.
There is provided a quality improving agent for iPS cells, including a polynucleotide, in which the polynucleotide contains an H1foo gene and a regulatory sequence that is capable of regulating at least one of the amount and the period of existence of an H1foo protein expressed from the H1foo gene in cells when the H1foo gene is transduced into the cells.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
Provided is a method for producing naive induced pluripotent stem cells from human somatic cells, comprising the following steps (1) to (3): (1) introducing one or more vectors containing a reprogramming factor into human somatic cells, (2) culturing said somatic cells in the presence of a naive medium, and (3) after step (2), culturing the resulting cells in the presence of the naive medium under the condition in which the amount of the vectors per the somatic cell is reduced to 30% or less of that at the start of step 3.
Provided is a method for producing naive induced pluripotent stem cells from human somatic cells, said method comprising the following steps (1) to (3): (1) a step for introducing at least one vector containing an initialization factor into human somatic cells; (2) a step for culturing the somatic cells in the presence of a naive medium; and (3) a step for, after step (2), culturing the obtained cells in the presence of the naive medium under conditions where the amount of the vector per somatic cell is reduced to 30% or less compared to the amount at the start of step 3.
A method for producing a cardiomyocyte including preparing a stem cell, introducing a Sendai virus into the stem cell by infection, expressing mRNA for synthesizing an inducing factor from the Sendai viruses in the stem cell to induce a cardiomyocyte from the stem cell.
A quality improving agent for iPS cells that comprises a polynucleotide, said polynucleotide containing H1foo gene and a regulatory sequence. When the H1foo gene is introduced into cells, the regulatory sequence can regulate the amount and/or timing of the presence of H1foo protein expressed by the H1foo gene in the cells.
The present invention provides a composition having a metabolism-improving action, which comprises a supernatant of brown adipocytes or a purified product thereof. The present invention also provides a method of preparing the supernatant without using a culture solution comprising a high concentration of glucose. The present invention also provides a method of producing brown adipocytes using pluripotent stem cells, which are useful for preparing the supernatant of brown adipocytes. The present invention has succeeded in obtaining a supernatant having a metabolism-improving action from brown adipocytes. It was also possible to obtain the supernatant without using a culture solution comprising a high concentration of glucose. The present invention has also succeeded in producing brown adipocytes from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail or the like. The brown adipocyte supernatant of the present invention is expected to be applied to the development of therapeutic agents and cosmetic products for glucose metabolism diseases.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
This method for producing cardiac muscle cells comprises: preparing stem cells; and inducing the stem cells into cardiac muscle cells by introducing a Sendai virus into the stem cells through infection and causing the Sendai virus to express mRNA for synthesizing an inducing factor inside the stem cells.
An objective of the present invention is to provide an improved negative-strand RNA viral vector and a use thereof, the negative-strand RNA viral vector exhibiting transient high expression of genes loaded in the vector and enabling the rapid removal of the vector after said expression. It was discovered that by adding a micro-RNA target sequence to the NP, P, or L gene of a negative-strand RNA viral vector, it is possible to control the expression of the vector depending on the micro-RNA expressed by the introduction cell. In particular, when a micro-RNA target sequence was added to the NP or P gene, the expression of the vector decreased depending on the micro-RNA, and the removal of the vector was promoted, while the effect was reversed when a micro-RNA target sequence was added to the L gene. The vector can be applied in cell therapy and regenerative medicine and can be used as a therapeutic vector that targets cancer.
NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE (Japon)
ID PHARMA CO., LTD. (Japon)
Inventeur(s)
Saeki, Kumiko
Oka, Masako
Matsumura, Kazunori
Shu, Tsugumine
Mori, Toyotaka
Abrégé
The present invention provides a peptide that promotes insulin secretion, and a use for said peptide. A search for insulin secretion promoting factors present in a culture supernatant of brown adipocytes (BA-SUP) derived from human pluripotent stem cells led to the identification of a bioactive peptide that promotes insulin secretion. Through the development of a peptide that imitates said peptide, it was discovered that a short-chain linear peptide capable of forming an α-helix structure exhibits strong insulin secretion promoting activity. Moreover, it was discovered that by heat-treating said peptide under acidic conditions or freeze-drying the peptide after dissolving in a buffer solution, the peptide becomes an active form having an increased insulin secretion promoting effect. Said peptide exhibited an effect of promoting insulin secretion using pancreatic beta cells, and of reducing the blood sugar level in vivo. The peptide group according to the present invention is expected to be applicable to the development of a therapeutic medication for glucose metabolism disorders.
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
Japan, as represented by the Director-General of National Institute of Infectious Disease (Japon)
ID Pharma Co., Ltd. (Japon)
Inventeur(s)
Matano, Tetsuro
Inoue, Makoto
Hara, Hiroto
Shu, Tsugumine
Abrégé
In this invention, a non-infectious particle has been produced, comprising a pathogen antigen protein caused to be expressed on the surface of a virus particle having at least one species of paramyxovirus envelope protein missing from the particle. This particle has been found to hold within the particle a large amount of antigen protein compared to an infectious particle, and to be capable of eliciting a host immune response with extremely high efficiency. The non-infectious particle according to the present invention is useful as a vaccine against a pathogenic virus, or the like.
NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE (Japon)
ID PHARMA CO., LTD. (Japon)
Inventeur(s)
Saeki, Kumiko
Kobayashi, Norihiko
Oka, Masako
Matsumura, Kazunori
Nishio, Miwako
Saeki, Koichi
Shu, Tsugumine
Mori, Toyotaka
Abrégé
Provided is a composition that comprises a supernatant of brown adipocytes or a purified product thereof and has a metabolism improving effect. Also provided is a method for preparing the aforesaid supernatant without using a liquid culture containing glucose at a high concentration. Also provided is a method for producing brown adipocytes using pluripotent stem cells, said method being useful for preparing a supernatant of brown adipocytes. In the present invention, a supernatant having a metabolism improving effect was successfully obtained from brown adipocytes. Also, this supernatant could be obtained without using a liquid culture containing glucose at a high concentration. In the present invention, moreover, brown adipocytes were successfully formed from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail, etc. The supernatant of brown adipocytes according to the present invention is expected as applicable to the development of therapeutic drugs for sugar metabolism-related diseases and cosmetics.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a technology for more efficient genetic modification, including target gene disruption, using a guide RNA-dependent nuclease. The present invention also addresses the problem of different cleavage efficiencies for each target sequence. Specifically, by the present invention, a new system was developed in which, when developing a target cleavage system that utilizes a guide RNA-dependent nuclease, only the nuclease gene is integrated into a negative-strand RNA viral vector, which has the properties of high infection efficiency and high transgene expression, and, after the viral vector has been introduced into cells in advance and the nuclease has been caused to be expressed, guide RNA is separately supplied to the cells. As a result, an increase in cleavage efficiency and a reduction in recleavage were both successfully achieved, and the efficiency of target gene modification was improved. The present invention is useful as an efficient genetic modification technology, and also has the feature of making it possible to adjust the enhancement and attenuation of genetic modification efficiency by adjusting cleavage efficiency through adjustment of the amount of guide RNA that is introduced.
JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (Japon)
ID PHARMA CO., LTD. (Japon)
Inventeur(s)
Matano, Tetsuro
Ishii, Hiroshi
Inoue, Makoto
Hironaka, Takashi
Shu, Tsugumine
Mori, Toyotaka
Abrégé
A polypeptide for selectively inducing a target antigen-specific CD8-positive T cell response is provided. Induction of vaccine-derived human immunodeficiency virus (HIV)-specific CD4-positive T cell response can promote HIV infection, so it would be useful to be able to obtain an HIV vaccine antigen that selectively induces an HIV-specific CD8-positive T cell response. In this invention, the amino acid sequence of a target antigen protein is divided into amino sequences of 8-12 residues, and a polypeptide antigen is designed in which these are linked in a sequence different from that of the original amino acid sequence. As a result of experiments on monkeys involving inoculation of vaccines using viral vectors and DNA expressing this antigen, it was shown that it is possible to efficiently and selectively induce an antigen-specific CD8-positive T cell response. This antigen is thought to be useful as a CD8-positive T cell-inducing vaccine antigen with extremely high selectivity.
Provided is a method for producing neural cells, the method including: preparing stems cells; and introducing Sendai virus into the stem cells via infection, and causing the Sendai virus to express induction-factor-synthesizing mRNA within the stem cells to induce the stem cells into neural cells.
The present invention provides a novel donor polynucleotide formed by connecting both ends of a genome fragment including a cleavable site, with a polynucleotide including a positive selection marker gene and a negative selection marker gene. The use of said donor polynucleotide enables cleavage to be performed in a homologous site of the donor polynucleotide without performing cleavage in a target gene locus, and as result thereof, it is possible to modify only the target gene while avoiding the possibility of "off-target," that is, the sequence other than the target sequence being modified.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
[Problem] To provide a composition for treating cancer, which has an effect to decrease the size of cancer occurring at a site remote from cancer to which the composition is administered (e.g., cancer transplanted on the opposite side of a body) and an effect to inhibit the metastasis of cancer or a tumor through a lymph system leading to the cancer or the tumor (i.e., lymph node metastasis). [Solution] A composition for treating cancer, which can be used for the lysis of metastatic cancer and comprises a complex containing genomic RNA of Sendai virus, wherein the genomic RNA comprises genomic RNA in which a nucleic acid encoding M protein is mutated or deleted, the genomic RNA encodes modified F protein in which a sequence for a cleavage site of the protein is substituted by a sequence capable of being cleaved with a protease incapable of cleaving wild-type F protein, and the genomic RNA further contains wild-type F protein of Sendai virus, and the complex is so configured as to inhibit the metastasis of a tumor to lymph node and the growth of distant metastatic cancer and to promote the regression of a lymph node metastasis when administered intratumorally.
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Protein in raw material form for scientific and medical research; enzymes for scientific and medical research; biochemicals, namely, polypeptides for in vitro and in vivo scientific and research use; chemical reagents comprising antibodies not for medical or veterinary purposes; chemical agents for chelating and sequestering; higher fatty acids for use in the field of scientific research, reagents, cosmetics, and pharmaceuticals Anti-cancer preparations; anti-sarcoma preparations; contrasting agent for X-ray imaging; diagnostic reagents for medical purposes; radio-isotope markers for therapeutic or diagnostic use; veterinary preparations for veterinary vaccines; biological preparations for the treatment of cancer, critical limb ischemia, cystic fibrosis, retinitis pigmentosa, AIDS, influenza, and Alzheimer's disease; preparations for gene therapy, namely, introducing genes to human and animal cells, tissues, organs and living bodies, and growth media for medical purposes; vaccines; gene vaccines; vectors for introducing genes to human and animal cells, tissues, organs and living bodies, and growth media for medical use, namely, for gene therapy Testing, inspection, research, or development of pharmaceuticals, cosmetics, or foodstuff; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; testing, inspection, research, or development of vaccines; testing, inspection, research, or development of recombinant proteins; medical, chemical, biochemical, biological and bacteriological research and functional analysis of genes or proteins; testing, inspection, or research related to technologies for manufacturing genetically engineered animals, plants, and vectors; testing, inspection, research, or development of vector technologies, namely, medical and scientific research in the field of genetics and genetic engineering; testing, inspection, or research on agriculture, livestock breeding, or fisheries; testing, inspection, research, or development of chemicals for life science
20.
INFECTIOUS DISEASE VACCINE USING NON-INFECTIOUS PARAMYXOVIRUS PARTICLE
JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (Japon)
ID PHARMA CO., LTD. (Japon)
Inventeur(s)
Matano, Tetsuro
Inoue, Makoto
Hara, Hiroto
Shu, Tsugumine
Abrégé
In this invention, a non-infectious particle has been produced, comprising a pathogen antigen protein caused to be expressed on the surface of a virus particle having at least one species of paramyxovirus envelope protein missing from the particle. This particle has been found to hold within the particle a large amount of antigen protein compared to an infectious particle, and to be capable of eliciting a host immune response with extremely high efficiency. The non-infectious particle according to the present invention is useful as a vaccine against a pathogenic virus, or the like.
The present invention provides a method for producing a motor neuron from a pluripotent stem cell, said method comprising the following steps: (1) introducing a single Sendai virus vector carrying a nucleic acid encoding Lhx3, a nucleic acid encoding Ngn2 and a nucleic acid encoding Isl1 into a pluripotent stem cell; and (2) culturing the pluripotent stem cell for 2 days or longer.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
An objective of the present invention is to provide an improved negative-strand RNA viral vector and a use thereof, the negative-strand RNA viral vector exhibiting transient high expression of genes loaded in the vector and enabling the rapid removal of the vector after said expression. It was discovered that by adding a micro-RNA target sequence to the NP, P, or L gene of a negative-strand RNA viral vector, it is possible to control the expression of the vector depending on the micro-RNA expressed by the introduction cell. In particular, when a micro-RNA target sequence was added to the NP or P gene, the expression of the vector decreased depending on the micro-RNA, and the removal of the vector was promoted, while the effect was reversed when a micro-RNA target sequence was added to the L gene. The vector can be applied in cell therapy and regenerative medicine and can be used as a therapeutic vector that targets cancer.
This invention relates to lentiviral gene transfer vectors pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
SHANGHAI PUBLIC HEALTH CLINICAL CENTER, FUDAN UNIVERSITY (Chine)
ID PHARMA CO., LTD. (Japon)
Inventeur(s)
Fan, Xiao-Yong
Shu, Tsugumine
Hu, Zhi-Dong
Lowrie, Douglas B.
Abrégé
Provided in the present invention are a recombinant Sendai virus vector vaccine expressing immunodominant antigens of mycobacterium tuberculosis, capable of being used as a therapeutic and preventative antituberculosis vaccine.
The present invention addresses the problem of providing an improved negative-strand RNA viral vector enabling transient high expression of a gene carried by the vector, and quick removal of the vector after the expression, and the use thereof. It was found that if a degron is added to a P-protein possessed by a negative-strand RNA viral vector, high-level expression of a gene carried by the vector is transiently induced after introduction of the vector, and thereafter, the vector can be quickly removed in a manner dependent on the degron. In particular, if the degron is added to a temperature-sensitive P-protein, the vector can be removed to a level below the detection limit within two weeks after cells are infected with the vector. Since the present invention is useful for transiently expressing a transcription factor, such as a reprogramming factor or the like, in target cells, and then quickly removing the vector, the present invention is expected to be applied in cell therapy and regenerative medicine.
The present invention provides methods for improving the efficiency of inducing pluripotent stem cells, as well as vectors and compositions for use therein. In the induction of pluripotent stem cells which contains the step of introducing a vector that contains the KLF gene, OCT gene, and SOX gene in this order, the efficiency of pluripotent stem cell induction was successfully increased significantly by further introducing a vector that contains the KLF gene but not the OCT gene and the SOX gene. The methods of the present invention have an excellent feature in that they allow efficient induction of pluripotent stem cells under a temperature condition closer to the physiological environment, and prompt vector removal after the pluripotent stem cell induction. The present invention enables more efficient induction of pluripotent stem cells.
An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.
[Problem] To provide a method and a recombinant vector that can efficiently produce myocardium-like cells. [Solution] A production method for myocardium-like cells, the method being characterized by using one or more Sendai virus vectors to introduce into fibroblasts one or more reprogramming factors selected from among the polypeptides Gata4, Mef2c, Tbx5, Mesp1, and Myocd, the Sendai virus vector(s) having in the genome thereof a nucleic acid that codes for said reprogramming factor(s). A composition for the production of myocardium-like cells, the composition including a Sendai virus vector that has a viral genome that contains one or more reprogramming factors selected from among the polypeptides Gata4, Mef2c, Tbx5, Mesp1, and Myocd.
This invention relates to lentiviral gene transfer vectors pseudotyped with hemagglutinin- neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/115 - Paramyxoviridae, p. ex. virus para-influenza
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
This invention relates to lentiviral gene transfer vectors pseudotyped with hemagglutinin- neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
35.
METHOD FOR IMPROVING EFFICIENCY OF INDUCING PLURIPOTENT STEM CELL
The present invention provides a method for improving the efficiency of inducing a pluripotent stem cell, and a vector and composition used for the method. The inventors succeeded in significantly increasing the efficiency of inducing a pluripotent stem cell by further introducing a vector including a KLF gene and not including an OCT gene and a SOX gene in pluripotent stem cell induction including a step for introducing a vector including a KLF gene, an OCT gene, and a SOX gene in this order. This method is capable of efficiently inducing a pluripotent stem cell under temperature conditions closer to a physiological environment, and has excellent characteristics in that the vector is rapidly eliminated after pluripotent stem cell induction. The present invention makes it possible to induce a pluripotent stem cell with greater efficiency.
Pluripotent stem cell-derived brown adipocytes, pluripotent stem cell-derived cell aggregate, method for producing same, and cell therapy and medical therapy therefor
National Center for Global Health and Medicine (Japon)
Inventeur(s)
Saeki, Kumiko
Yuo, Akira
Nishio, Miwako
Kawasaki, Masako
Saeki, Koichi
Hasegawa, Mamoru
Abrégé
Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical reagents (other than for medical or veterinary
purposes); proteins (raw material); enzymes; polypeptides;
polynucleotides (other than for medical or veterinary
purposes); chemical reagents comprising antibodies (other
than for medical or veterinary purposes); chemical agents;
higher fatty acids. Anti-cancer preparations; anti-sarcoma preparations;
contrasting agent for X-ray imaging; diagnostic reagents for
medical purposes; radio-isotope markers for therapeutic or
diagnostic use; veterinary preparations; biological
preparations for medical purposes; preparations for gene
therapy; vaccines; gene vaccines; vectors for gene therapy. Testing, inspection, research, or development of
pharmaceuticals, cosmetics, or foodstuff; testing,
inspection, research, or development of preparations for
gene therapy; testing, inspection, research, or development
of vaccines; testing, inspection, research, or development
of recombinant proteins; functional analysis of genes or
proteins; testing, inspection, or research related to
technologies for manufacturing genetically engineered
animals, plants, and vectors; testing, inspection, research,
or development of vector technologies; testing, inspection,
or research on agriculture, livestock breeding, or
fisheries; testing, inspection, research, or development of
chemicals for life science; testing or research on machines
and instruments; computer software design, computer
programming, or maintenance of computer software; rental of
computers or providing computer programs.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical reagents (other than for medical or veterinary
purposes); proteins (raw material); enzymes; polypeptides;
polynucleotides (other than for medical or veterinary
purposes); chemical reagents comprising antibodies (other
than for medical or veterinary purposes); chemical agents;
higher fatty acids. Anti-cancer preparations; anti-sarcoma preparations;
contrasting agent for X-ray imaging; diagnostic reagents for
medical purposes; radio-isotope markers for therapeutic or
diagnostic use; veterinary preparations; biological
preparations for medical purposes; preparations for gene
therapy; vaccines; gene vaccines; vectors for gene therapy. Testing, inspection, research, or development of
pharmaceuticals, cosmetics, or foodstuff; testing,
inspection, research, or development of preparations for
gene therapy; testing, inspection, research, or development
of vaccines; testing, inspection, research, or development
of recombinant proteins; functional analysis of genes or
proteins; testing, inspection, or research related to
technologies for manufacturing genetically engineered
animals, plants, and vectors; testing, inspection, research,
or development of vector technologies; testing, inspection,
or research on agriculture, livestock breeding, or
fisheries; testing, inspection, research, or development of
chemicals for life science; testing or research on machines
and instruments; computer software design, computer
programming, or maintenance of computer software; rental of
computers or providing computer programs.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical reagents not for medical or veterinary purposes; [ protein in raw material form for scientific and medical research; enzymes for scientific and medical research; biochemicals, namely, polypeptides for in vitro and in vivo scientific and research use; ] biochemicals, namely, polynucleotides for in vitro and in vivo scientific and research use [ ; chemical reagents comprising antibodies not for medical or veterinary purposes; chemical agents for chelating and sequestering; higher fatty acids for use in the field of scientific research, reagents, cosmetics, and pharmaceuticals ] [ Anti-cancer preparations; anti-sarcoma preparations; contrasting agent for X-ray imaging; diagnostic reagents for medical purposes; radio-isotope markers for therapeutic or diagnostic use; veterinary preparations for veterinary vaccines; biological preparations for the treatment of cancer, critical limb ischemia, cystic fibrosis, retinitis pigmentosa, AIDS, influenza, and Alzheimer's disease; preparations for gene therapy, namely, introducing genes to human and animal cells, tissues, organs and living bodies, and growth media for medical purposes; vaccines; gene vaccines; vectors for introducing genes to human and animal cells, tissues, organs and living bodies, and growth media for medical use, namely, for gene therapy ] [ Testing, inspection, research, or development of pharmaceuticals, cosmetics, or foodstuff; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; testing, inspection, research, or development of vaccines; testing, inspection, research, or development of recombinant proteins; medical, chemical, biochemical, biological and bacteriological research and functional analysis of genes or proteins; testing, inspection, or research related to technologies for manufacturing genetically engineered animals, plants, and vectors; testing, inspection, research, or development of vector technologies, namely, medical and scientific research in the field of genetics and genetic engineering; testing, inspection, or research on agriculture, livestock breeding, or fisheries; testing, inspection, research, or development of chemicals for life science ]
41.
Methods for producing minus-strand RNA viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken β-actin promoter
The present invention provides methods for producing a minus-strand RNA viral vector, which comprise using a promoter comprising a cytomegalovirus enhancer and a chicken β-actin promoter, to induce the transcription of the genome RNA of a minus-strand RNA viral vector and the expression of minus-strand RNA viral proteins that form a ribonucleoprotein with the genome RNA. The methods of the present invention enable high efficiency production of highly safe minus-strand RNA viral vectors. The methods of the present invention are particularly useful for producing minus-strand RNA viral vectors that are deficient in envelope-constituting protein genes.
A gene is successfully transferred into airway epithelial stem cells by using a monkey immunodeficiency virus vector having been pseudotyped with Sendai virus envelope glycoproteins F and HN. This gene transfer into airway epithelial stem cells with the use of the vector as described above is useful in gene therapy for a hereditary respiratory disease such as cystic fibrosis. Moreover, it becomes possible to select a respiratory organ such as the lung as a tissue that is capable of producing and supplying a protein deficient in a hereditary disease.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C07K 14/115 - Paramyxoviridae, p. ex. virus para-influenza
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
The present invention provides methods for producing a minus-strand RNA viral vector, which comprise using a promoter comprising a cytomegalovirus enhancer and a chicken .beta.-actin promoter, to induce the transcription of the genome RNA of a minus-strand RNA viral vector and the expression of minus-strand RNA viral proteins that form a ribonucleoprotein with the genome RNA. The methods of the present invention enable high efficiency production of highly safe minus-strand RNA viral vectors. The methods of the present invention are particularly useful for producing minus-strand RNA viral vectors that are deficient in envelope-constituting protein genes.
